Article Text

Download PDFPDF
Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer
  1. Hao Bai1,
  2. Jinjing Xia1,
  3. Xiaokai Zhao2,
  4. Ziying Gong2,
  5. Daoyun Zhang2,
  6. liwen Xiong1
  1. 1Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
  2. 2Shanghai Yunying Medical Technology Co, Shanghai, China
  1. Correspondence to Dr liwen Xiong, Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China; zxk{at}


Purpose Circulating tumour DNA (ctDNA) is a promising biomarker for detection of non-invasive epidermal growth factor receptor (EGFR) mutations in patients with non-small-cell lung cancer (NSCLC). However, the existing methods have limitations in sensitivity or in availability. The aim was to evaluate the accuracy of capture target sequencing for detecting EGFR mutations in ctDNA.

Methods A total of 79 patients with NSCLC and available plasma and matched tissue specimens were enrolled. Through capture target sequencing, mutations were searched in over 20 000 reads obtained from each exon region. Parameters corresponding to the limit of detection and limit of quantification were used as the thresholds for mutation detection. To evaluate the accuracy, detection of EGFR mutations in matched tissue samples was performed by target capture sequencing and the amplification refractory mutation system (ARMS).

Results EGFR mutations were discovered in 32.9 % (26/79) of the patients with NSCLC, the overall rate of consistency for the 79 paired plasma and tissue samples was 86.1 % (68/79). The sensitivity and specificity of detecting EGFR mutations in the plasma were 72.7 % and 95.7 %. In terms of the EGFR mutations identified by ARMS, the overall consistency was 78.5 % (62/79) in three groups. Of 21 patients with EGFR sensitive mutation defined by next generation sequencing in ctDNA, 20 (95.2%) showed long-term disease control with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment; the median progression-free survival was 10.8 months (95% CI 9.1 to 16.8).

Conclusions Target capture sequencing of ctDNA can be used for genotyping of EGFR in patients with NSCLC, which may enable a direct recommendation for EGFR TKI on the basis of positive results with plasma DNA.

  • circulating tumor DNA
  • EGFR mutations
  • target capture sequencing

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Runjan Chetty.

  • HB and JX contributed equally.

  • Contributors IW, DZ and ZG designed the experiments; HB and JX were involved in project administration; HB, JX and XZ wrote and edited the manuscript; HB, JX, ZG, and XZ performed experiments and analysed the data. All authors have read and approved the final manuscript.

  • Funding This work was also supported by Shanghai Municipal Commission of Health and Family Planning (201440032).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Linked Articles